Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series.

Autor:	Osmanodja B; Department of Nephrology and Intensive Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Berlin Institute of Health, Humboldt-Universität zu Berlin, Berlin, Germany., Akifova A; Department of Nephrology and Intensive Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Berlin Institute of Health, Humboldt-Universität zu Berlin, Berlin, Germany., Budde K; Department of Nephrology and Intensive Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Berlin Institute of Health, Humboldt-Universität zu Berlin, Berlin, Germany., Oellerich M; Department of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany., Beck J; Chronix Biomedical GmbH, Göttingen, Germany., Bornemann-Kolatzki K; Chronix Biomedical GmbH, Göttingen, Germany., Schütz E; Chronix Biomedical GmbH, Göttingen, Germany., Velden J; Department of Nephropathology, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany., Lehmann C; Institute for Transfusion Medicine, Laboratory for Transplantation Immunology, University Hospital Leipzig, Leipzig, Germany., Krüger BM; Medical Department III, Division of Nephrology, University of Leipzig Medical Center, Leipzig, Germany., Bachmann A; Medical Department III, Division of Nephrology, University of Leipzig Medical Center, Leipzig, Germany., Kowald J; Medical Department III, Division of Nephrology, University of Leipzig Medical Center, Leipzig, Germany.
Jazyk:	angličtina
Zdroj:	Transplant international : official journal of the European Society for Organ Transplantation [Transpl Int] 2024 Aug 01; Vol. 37, pp. 13213. Date of Electronic Publication: 2024 Aug 01 (Print Publication: 2024).
DOI:	10.3389/ti.2024.13213
Abstrakt:	Antibody-mediated rejection (AMR) is among the most frequent causes for graft loss after kidney transplantation. While there are no approved therapies, several case reports with daratumumab and the very recent phase 2 trial of felzartamab in AMR have indicated the potential efficacy of therapeutic interventions targeting CD38. Donor-derived cell-free DNA (dd-cfDNA) is an emerging biomarker with injury-specific release and a short half-life, which could facilitate early diagnosis of AMR and monitoring of treatment response. We describe two cases of patients with chronic active AMR, who were treated with monthly daratumumab infusions, and in whom donor-derived cell-free DNA (dd-cfDNA) was measured longitudinally to monitor treatment response. In both patients, daratumumab treatment led to stabilization of kidney function parameters, a strong decline of dd-cfDNA below the previously established threshold for rejection, and partial or complete histologic resolution of AMR activity. Our case series suggests that dd-cfDNA may be a useful companion biomarker for longitudinal monitoring of anti-CD38 treatment in patients with AMR. Competing Interests: The authors of this manuscript have conflicts of interest to disclose. BO received travel reimbursement from Oncocyte. MO acts as a consultant to Oncocyte. JB, KB-K, and ES are employees of Chronix Biomedical GmbH, a subsidiary of Chronix Biomedical Inc. (an Oncocyte company), which holds intellectual property rights (EP 3004388B1, EP3201361B1, and US10570443B2). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Osmanodja, Akifova, Budde, Oellerich, Beck, Bornemann-Kolatzki, Schütz, Velden, Lehmann, Krüger, Bachmann and Kowald.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu